• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nuclea Biotechnologies acquires Oncogene Science, extends Wilex cooperation

Nuclea Biotechnologies acquires Oncogene Science, extends Wilex cooperation

September 9, 2013
CenterWatch Staff

Pittsfield, Mass.-based Nuclea Biotechnologies has acquired all shares of Cambridge, Mass.-based Wilex (Oncogene Science), a wholly owned U.S. subsidiary of Wilex.

Nuclea will assume all assets of Oncogene Science and responsibility for repayment of $2.5 million under an intercompany loan between Oncogene Science and Wilex. In addition, Wilex is eligible for single-digit royalties on net sales on the HER-2/neu and CAIX assays.

Concurrently and as an essential part of the overall deal, Wilex and Nuclea entered  a development agreement under which Nuclea will develop an automated CAIX IVD IHC assay (CAIX Dx) to be submitted for FDA allowance under the investigational device exemption. CAIX Dx is intended to be used for patient stratification in a planned pivotal study with RENCAREXand as a potential future companion diagnostic in the adjuvant treatment of clear cell renal cell carcinoma. Nuclea will bear the costs for the development of CAIX Dx as a contribution in kind, which will lead to savings of at least $2.5 million for Wilex.

Oncogene Science specializes in serum based oncoprotein diagnostics and provides the only FDA cleared and CE marked IVD ELISA test for the measurement of serum HER-2/neu in the management and monitoring of patients with metastatic breast cancer. In addition, the company listed the CAIX IHC kit as a Class I 510(k)-exempt medical device with the FDA. This immunohistochemistry (IHC) kit is used to identify the antigen Carbonic Anhydrase IX (CAIX) which plays an important role in various types of cancer.

Nuclea identifies biomarkers and develops proprietary diagnostic assays under the brand Decision Dx that can help predict which courses of treatments will be effective for specific patients, based on their genetic makeup. Nuclea performs in vitro diagnostic assays in the area of oncology in a certified laboratory (CLIA) and also has access through its business relationships with hospitals and research institutions to patients in need of such tests. One such assay is Nuclea’s Decision Dx Fatty Acid Synthase for use in a variety of cancers.

Nuclea and Oncogene Science have been partners in marketing the serum HER-2/neu ELISA since early 2013 and had identified several synergies. The agreement includes the transfer to Nuclea of numerous distribution and marketing agreements for the marketed Oncogene Science tests and Nuclea will acquire the Good Manufacturing Practice (GMP) facility in Cambridge.

“This deal is a major step for Nuclea,” said Patrick J. Muraca, president and chief executive officer of Nuclea. “The commercial platform and the GMP facility acquired through this transaction will serve as a catalyst for the adoption of Nuclea’s Decision Dx Fatty Acid Synthase, which is currently available as a CLIA validated assay, used in clinical trials and under regulatory review.”   

Professor Olaf G. Wilhelm, chief executive officer of Oncogene Science and Wilex, said, “The acquisition of Oncogene Science was driven by the CAIX assets. The future development of RENCAREX requires now a companion diagnostic based on CAIX for patient stratification. This transaction delivers not only a partner to develop and commercialise the CAIX Dx, but also further cost savings and allows Wilex to focus on its late-stage drug pipeline and ADC technology platform.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing